Kaoru Funabashi

Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito et al. · Cancer Research · 2020 · 198 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

In Vitro Biological Profile of a Highly Potent Novel Endothelin (ET) Antagonist BQ-123 Selective for the ETA Receptor

Masaki Ihara, Kiyofumi Ishikawa, Takahiro Fukuroda et al. · Journal of Cardiovascular Pharmacology · 1992 · 116 citations

Medicine, Medicinal Chemistry, Pharmacology +10

TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant <i>EGFR</i> Mutations

Hibiki Udagawa, Shinichi Hasako, Akihiro Ohashi et al. · Molecular Cancer Research · 2019 · 72 citations · Full text

Medicine, Oncology, Pharmacology +15

Discovery of 3-Ethyl-4-(3-isopropyl-4-(4-(1-methyl-1<i>H</i>-pyrazol-4-yl)-1<i>H</i>-imidazol-1-yl)-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available HSP90 Inhibitor

Takao Uno, Yuichi Kawai, Satoshi Yamashita et al. · Journal of Medicinal Chemistry · 2018 · 55 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Structural Basis of Human p70 Ribosomal S6 Kinase-1 Regulation by Activation Loop Phosphorylation

T. Sunami, Noel Byrne, Ronald E. Diehl et al. · Journal of Biological Chemistry · 2009 · 54 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +16